Table 6.
CD8+ T cell outcomes in peripheral blood.
| FIRST AUTHOR YEAR |
TOTAL (N) | ENDOMETRIOSIS (N) | CONTROLS (N) | UTERINE CYCLE PHASE (N) | ANALYZED SAMPLES OF THE TOTAL(N) | CD8+ T CELL FINDINGS IN ENDOMETRIOSIS VERSUS CONTROLS | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage I/II | Stage III/IV | Subfertility | Age (yrs)* | Diagnosis | Subfertility | Age (yrs)* | Proliferative | Secretory | Endometriosis | Controls | Cell proportion | Activation and cytotoxicity | ||
| Chen, 2017 |
63 | 14 | 18 | N/A | 29 (18–38) |
Non-endometrial pathology | N/A | 32 (19–44) |
63 | 0 | 4 | 4 | NO DIFFERENCE among CD3+ cells. | |
| Correa, 2022 |
73 | 0 | 47 | N/A | 34.3 ( ± 6.2) | Tubal ligation | N/A | 34.5 ( ± 4.6) | 29 | 44 | 47 | 26 | NO DIFFERENCE in CD8+ iNKT cell subset. | NO DIFFERENCE in levels of IL-17, IL-10 or IL-6 expressing CD8+ iNKT cells. |
| D’Hooghe, 1996 |
60 | 20 | 13 | N/A | N/A | Healthy | N/A | N/A | 21 | 20 | 37 | 23 |
NO DIFFERENCE among leukocytes. NO DIFFERENCE among leukocytes between spontaneous and induced endometriosis. |
|
| Gagne, 2003 |
306 | N/A | N/A | 29 | 31–44 (69%) | Tubal ligation/reanastomosis | 0 | 31–44 (72%) | 160 | 137 | 175 | 131 |
NO DIFFERENCE among leukocytes. NO DIFFERENCE in CD8+ cells among leukocytes. |
|
| Gymrek, 2008 |
48 | 13 | 23 | N/A | 23–53 | Non-endometrial pathology | N/A | 27–51 | 20 | 28 | 25 | 11 |
NO DIFFERENCE among CD3+ cells. NO DIFFERENCE among CD3+ cells between different stages. |
NO DIFFERENCE in the ratio of IFN-gamma, TNF-alpha or IL-8 expressing cells. |
| Ho, 1995 |
29 | 8 | 11 | N/A | N/A | Tubal ligation | 0 | N/A | 29 | 0 | 19 | 10 | NO DIFFERENCE in HLA-DR+, CD25+, CD28+ and CD69+ subsets between mild and severe endometriosis and controls. | |
| Hsu, 1997 |
52 | 0 | 26 | 26 | 26–41 | Healthy | 0 | 22–38 | N/A | N/A | 26 | 26 | NO DIFFERENCE in CD8+CD11b- or CD8+CD11b+ level and ratio among lymphocytes. | |
| Li, 2019 |
50 | 17 | 15 | N/A | 32.6 ( ± 1.10) | Non-endometrial pathology | N/A | 33.3 ( ± 1.23) | 50 | 0 | 32 | 18 | NO DIFFERENCE among MAIT population. | |
| Liu, 2020 |
101 | 0 | 33 | 33 | 30 (27–33) | Healthy | 0 | 30 (27–32) | N/A | N/A | 33 | 68 |
INCREASED levels of central memory subtypes (CD3+CD8+CD45RA-CCR7+; p < 0.05). DECREASED levels of terminally differentiated effector memory subtypes (CD3+CD8+CD28−; p = 0.006). |
|
| Mier-Cabrera, 2011 |
62 | 32 | 0 | 32 | 32.7 ( ± 2.5) | Tubal ligation | 0 | 33.8 ( ± 5.4) | 0 | 62 | 32 | 30 | NO DIFFERENCE among lymphocytes. | NO DIFFERENCE in the ratio of IFN-gamma and IL-2 expressing subsets |
| Muharam, 2022 | 14 | N/A | N/A | N/A | 30.57 ± 2.33 | Non-endometrial pathology | N/A | 33.71 ± 2.14 | N/A | N/A | 7 | 7 | NO DIFFERENCE in CD8+CD28+ cells. | |
| Opsahl, 1994 |
20 | 8 | 0 | 8 | N/A | Tubal ligation | 0 | N/A | 11 | 9 | 8 | 12 | NO DIFFERENCE among PBMCs. | |
| Schmitz, 2021 |
23 | 6 | 6 | N/A | 33.7 (± 6.3) | Healthy | N/A | 32.5 ( ± 7.2) |
23 | 0 | 12 | 11 | NO DIFFERENCE among CD3+ cells. | NO DIFFERENCE in the ratio of perforin high subsets. |
| Sobstyl, 2020 |
80 | 22 | 21 | 14 | 35.5 ( ± 8.0) | Healthy | N/A | 36.1 ( ± 10.7) | N/A | N/A | 40 | 40 |
NO DIFFERENCE among leukocytes. INCREASED CD8+TLR-2+ among CD8 T cells (p = 0.0054). NO DIFFERENCE in CD3+CD8+ and CD8+ TLR-2+ between different stages of endometriosis. |
|
N/A, Not available; scRNAseq, Single cell RNA sequencing; IHC, Immunohistochemistry; GSEA, Gene set enrichment analysis; FC, Flow cytometry; Age (yrs)*: Mean ± SD or Median (Range).